Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
Status: | Active, not recruiting |
---|---|
Conditions: | Depression, Depression, Major Depression Disorder (MDD) |
Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 12 - 21 |
Updated: | 1/26/2018 |
Start Date: | October 2015 |
End Date: | December 2018 |
A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents
To evaluate the safety and efficacy of daily, active Neurostar® TMS (when compared with sham
treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
treatment) in adolescents meeting criteria for Major Depressive Disorder (MDD).
To evaluate the antidepressant effects of daily, active TMS (when compared with sham
treatment) in adolescents meeting criteria for Major Depressive Disorder, single or recurrent
episode (Phase I).
Secondary:
To evaluate the acute and long term safety of TMS treatment in adolescent MDD subjects.
To evaluate the durability of benefit of TMS treatment over the course of 6 months in
subjects who received clinical benefit from acute treatment course(s) (Phase III).
To evaluate the benefit of daily, active, open-label TMS in Phase I subjects who did not
receive protocol-defined clinical benefit; as new acute treatment (sham to active) or as
extended treatment course (blinded active to open label active) (Phase II).
treatment) in adolescents meeting criteria for Major Depressive Disorder, single or recurrent
episode (Phase I).
Secondary:
To evaluate the acute and long term safety of TMS treatment in adolescent MDD subjects.
To evaluate the durability of benefit of TMS treatment over the course of 6 months in
subjects who received clinical benefit from acute treatment course(s) (Phase III).
To evaluate the benefit of daily, active, open-label TMS in Phase I subjects who did not
receive protocol-defined clinical benefit; as new acute treatment (sham to active) or as
extended treatment course (blinded active to open label active) (Phase II).
Inclusion Criteria:
- Primary diagnosis of unipolar major depressive disorder, in a current major depressive
episode, without psychotic features
- Duration of current episode of depression ≥4 weeks and ≤3 years
- Clinical Global Impression - Severity of Illness ≥ 4
- Resistance to antidepressant treatment in a discrete illness episode
- HAMD24 Item 1 ≥ 2 and total score ≥ 20
- Subjects able to commit to protocol visit schedule
- At the end of the baseline visit, subject must have a HAMD24 score of ≥ 18 and change
in score may not be ≥ 25% decrease from that seen at the screening visit
Exclusion Criteria:
- Prior TMS, vagus nerve stimulation (VNS), or electroconvulsive therapy (ECT)
- Contraindication to TMS
- Cardiac pacemakers, implanted medication pumps, intracardiac lines
- History of neurological disorder
- Unstable medical conditions
- Any psychiatric disorder, which in the judgement of the Investigator may hinder the
subject in completing the procedures required by the study protocol.
- Significant acute suicide risk
- Inability to locate and quantify a motor threshold
- If sexually active female, not on an accepted method of birth control.
- Diagnoses of the following conditions (current unless otherwise stated):
- Depression secondary to a general medical condition, or substance induced:
- Seasonal pattern of depression as defined by Diagnostic and Statistical Manual of
Mental Disorders (DSM-5)
- Any psychotic disorder (lifetime), including history of schizophrenia,
schizoaffective disorder, other psychosis, psychotic features in this or previous
episodes, amnestic disorder,
- Intellectually disabled,
- Substance dependence or abuse within the past year (except nicotine or caffeine),
- Bipolar disorder,
- Obsessive compulsive disorder (lifetime),
- Post-traumatic stress disorder (lifetime),
- Eating disorder (lifetime).
We found this trial at
13
sites
Rochester, Minnesota 55905
Principal Investigator: Paul Croarkin, MD
Phone: 507-255-0624
Click here to add this to my saved trials
Baltimore, Maryland 21285
Principal Investigator: Scott Aaronson, MD
Phone: 410-938-3136
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Mark George, MD
Phone: 843-876-5141
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Cincinnati, Ohio 45267
Principal Investigator: Jeffrey R Strawn, MD
Phone: 513-558-2931
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: Kevin Reeves, MD
Phone: 614-685-8754
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
Click here to add this to my saved trials
Dothan, Alabama 36303
Principal Investigator: Emmalynn McDowell, MD
Phone: 334-702-7222
Click here to add this to my saved trials
Gainesville, Florida 32606
Principal Investigator: Richard Holbert, MD
Phone: 352-273-8540
Click here to add this to my saved trials
Grand Junction, Colorado 81501
Principal Investigator: Robert Sammons, MD
Phone: 970-697-1020
Click here to add this to my saved trials
Los Angeles, California 90095
(310) 825-4321
Principal Investigator: Andrew Leuchter, MD
Phone: 310-825-7471
UCLA UCLA's primary purpose as a public research university is the creation, dissemination, preservation and...
Click here to add this to my saved trials
Louisville, Kentucky 40222
Principal Investigator: G. Randolph Schrodt, MD
Phone: 502-930-7881
Click here to add this to my saved trials
Palo Alto, California 94304
Principal Investigator: H. Brent Solvason, MD
Phone: 650-723-8323
Click here to add this to my saved trials
Pensacola, Florida 32502
Principal Investigator: Pashia Groom, PhD
Phone: 850-433-1656
Click here to add this to my saved trials
South Bend, Indiana
Principal Investigator: Ahmed Elmaadawi, MD
Phone: 547-647-6584
Click here to add this to my saved trials